Thermo Fisher Scientific Acquires CorEvitas from Audax Private Equity

Thermo Fisher Scientific agreed to acquire CorEvitas, a Waltham, Massachusetts–based real-world evidence (RWE) and clinical registries provider, from Audax Private Equity for $912.5 million in cash. The acquisition, completed August 14, 2023, will fold CorEvitas (approximately 300 employees; expected 2023 revenue ~$110M) into Thermo Fisher’s Laboratory Products and Biopharma Services segment to expand its RWE and life‑sciences data capabilities.